The National Agency for Food and Drug Administration and Control (NAFDAC) has announced a recall of a batch of Deekins Amoxycillin following reports of adverse reactions among patients. The affected batch, identified as Batch No. AMX2023/05, has been distributed nationwide and was found to cause unexpected side effects, prompting immediate action from the regulatory body.
In a statement released on Monday, NAFDAC emphasized the importance of public safety and urged healthcare providers, pharmacies, and patients to immediately discontinue the use of this batch. The adverse reactions reported include severe allergic responses, gastrointestinal disturbances, and rashes. These symptoms prompted investigations that revealed possible quality and safety concerns with the specific batch.
Amoxycillin, a commonly used antibiotic, is typically prescribed for bacterial infections, including respiratory, ear, and urinary tract infections. NAFDAC’s proactive recall highlights its commitment to maintaining pharmaceutical standards and safeguarding public health. The agency has called on all stakeholders to return the affected products to the nearest NAFDAC office or authorized collection centers.
Dr. Mojisola Adeyeye, the Director-General of NAFDAC, reassured the public that comprehensive testing and quality control measures are underway to determine the root cause of the issue. She also advised consumers to remain vigilant and report any further adverse reactions through NAFDAC’s official reporting channels.
NAFDAC continues to emphasize its zero-tolerance policy towards compromised product quality and urges cooperation in ensuring the safety of medications in circulation.
